Cryoport, Inc. (NASDAQ:CYRX – Free Report) – Investment analysts at Roth Capital lowered their Q3 2024 earnings per share estimates for shares of Cryoport in a research report issued on Wednesday, August 7th. Roth Capital analyst R. Baldry now expects that the company will earn ($0.33) per share for the quarter, down from their previous estimate of ($0.31). The consensus estimate for Cryoport’s current full-year earnings is ($1.39) per share. Roth Capital also issued estimates for Cryoport’s Q4 2024 earnings at ($0.30) EPS, Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.29) EPS and FY2025 earnings at ($1.16) EPS.
Cryoport (NASDAQ:CYRX – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($1.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($1.25). Cryoport had a negative return on equity of 15.19% and a negative net margin of 50.17%. The firm had revenue of $57.60 million for the quarter, compared to analyst estimates of $57.65 million. During the same period in the previous year, the company posted ($0.42) EPS. Cryoport’s revenue was up 1.0% on a year-over-year basis.
Read Our Latest Stock Analysis on Cryoport
Cryoport Price Performance
Shares of NASDAQ CYRX opened at $8.23 on Friday. The stock’s 50-day moving average is $8.47 and its two-hundred day moving average is $13.13. The company has a debt-to-equity ratio of 0.86, a current ratio of 10.73 and a quick ratio of 10.22. Cryoport has a 1-year low of $5.32 and a 1-year high of $20.10. The company has a market cap of $405.39 million, a price-to-earnings ratio of -3.33 and a beta of 1.59.
Hedge Funds Weigh In On Cryoport
Several hedge funds have recently bought and sold shares of CYRX. Cadian Capital Management LP increased its position in Cryoport by 30.4% during the fourth quarter. Cadian Capital Management LP now owns 3,464,079 shares of the company’s stock worth $53,659,000 after buying an additional 807,340 shares in the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Cryoport by 46.9% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,992,895 shares of the company’s stock valued at $30,870,000 after purchasing an additional 636,395 shares during the period. Assenagon Asset Management S.A. grew its position in shares of Cryoport by 52.9% in the second quarter. Assenagon Asset Management S.A. now owns 1,477,693 shares of the company’s stock valued at $10,211,000 after purchasing an additional 511,064 shares during the period. Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Cryoport in the first quarter valued at $7,800,000. Finally, New York State Common Retirement Fund grew its position in shares of Cryoport by 29.9% in the fourth quarter. New York State Common Retirement Fund now owns 1,642,752 shares of the company’s stock valued at $25,446,000 after purchasing an additional 378,340 shares during the period. Hedge funds and other institutional investors own 92.90% of the company’s stock.
Insiders Place Their Bets
In other news, Director Richard J. Berman sold 8,105 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $13.41, for a total value of $108,688.05. Following the completion of the sale, the director now directly owns 100,000 shares of the company’s stock, valued at approximately $1,341,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Edward J. Zecchini sold 3,443 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $13.37, for a total value of $46,032.91. Following the completion of the transaction, the insider now directly owns 60,051 shares of the company’s stock, valued at approximately $802,881.87. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Richard J. Berman sold 8,105 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $13.41, for a total value of $108,688.05. Following the completion of the transaction, the director now directly owns 100,000 shares of the company’s stock, valued at $1,341,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,715 shares of company stock valued at $188,224. 10.10% of the stock is owned by company insiders.
About Cryoport
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
See Also
- Five stocks we like better than Cryoport
- Golden Cross Stocks: Pattern, Examples and Charts
- MarketBeat Week in Review – 8/5 – 8/9
- Investing in the High PE Growth Stocks
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Upcoming IPO Stock Lockup Period, Explained
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.